AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 15, 2026

Daily Signals

2696 companies scored · 2026-10-15 run in progress: 5121 of ~5380 signals so far · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-15 Cut-offs from the 2026-10-15 run
Companies scored 2696 IC ≥ 0 · market cap ≥ $100M
Median forecast +2.60% Total · 90D
Long–short spread +5.94% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 425 ▼ 593 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

304 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
151 TYRATyra Biosciences, Inc. Life Sciences 0.22 $1.1B Unlock rating and forecasts
152 LBRXLB PHARMACEUTICALS INC Life Sciences 0.20 $1.1B Unlock rating and forecasts
153 REPLReplimune Group, Inc. Life Sciences 0.36 $1.1B Unlock rating and forecasts
154 MNKDMANNKIND CORP Life Sciences 0.62 $971M Unlock rating and forecasts
155 QDELQuidelOrtho Corp Life Sciences 0.05 $951M Unlock rating and forecasts
156 IMTXImmatics N.V. Life Sciences 0.34 $938M Unlock rating and forecasts
157 MGTXMeiraGTx Holdings plc Life Sciences 0.30 $904M Neutral +0.75% +2.61% ·
158 CGEMCullinan Therapeutics, Inc. Life Sciences 0.40 $901M Unlock rating and forecasts
159 ANROAlto Neuroscience, Inc. Life Sciences 0.21 $888M Unlock rating and forecasts
160 RIGLRIGEL PHARMACEUTICALS INC Life Sciences 0.06 $875M Neutral +0.73% +2.40% ▼ 1
161 ABUSArbutus Biopharma Corp Life Sciences 0.05 $849M Unlock rating and forecasts
162 CYRXCryoport, Inc. Life Sciences 0.30 $843M Unlock rating and forecasts
163 GLUEMonte Rosa Therapeutics, Inc. Life Sciences 0.15 $839M Unlock rating and forecasts
164 AVBPArriVent BioPharma, Inc. Life Sciences 0.18 $828M Unlock rating and forecasts
165 ALMSALUMIS INC. Life Sciences 0.28 $817M Unlock rating and forecasts
166 ARDXARDELYX, INC. Life Sciences 0.38 $815M Neutral +0.60% +2.12% ▼ 1
167 HELPHelus Pharma Inc. Life Sciences 0.18 $782M Unlock rating and forecasts
168 DNAGinkgo Bioworks Holdings, Inc. Life Sciences 0.30 $776M Unlock rating and forecasts
169 GERNGERON CORP Life Sciences 0.10 $765M Unlock rating and forecasts
170 COLLCOLLEGIUM PHARMACEUTICAL, INC Life Sciences 0.63 $755M Unlock rating and forecasts
171 IVAInventiva S.A. Life Sciences 0.24 $749M Unlock rating and forecasts
172 ACHVACHIEVE LIFE SCIENCES, INC. Life Sciences 0.40 $717M Unlock rating and forecasts
173 LXRXLEXICON PHARMACEUTICALS, INC. Life Sciences 0.43 $712M Unlock rating and forecasts
174 IMMXImmix Biopharma, Inc. Life Sciences 0.29 $706M Unlock rating and forecasts
175 GYREGYRE THERAPEUTICS, INC. Life Sciences 0.02 $699M Unlock rating and forecasts
176 VSTMVerastem, Inc. Life Sciences 0.47 $698M Unlock rating and forecasts
177 SANASana Biotechnology, Inc. Life Sciences 0.28 $698M Unlock rating and forecasts
178 ANNXAnnexon, Inc. Life Sciences 0.31 $682M Unlock rating and forecasts
179 CADLCandel Therapeutics, Inc. Life Sciences 0.41 $682M Unlock rating and forecasts
180 FDMT4D Molecular Therapeutics, Inc. Life Sciences 0.22 $674M Unlock rating and forecasts
181 AURAAura Biosciences, Inc. Life Sciences 0.43 $657M Unlock rating and forecasts
182 AVTXAvalo Therapeutics, Inc. Life Sciences 0.29 $644M Unlock rating and forecasts
183 CLYMClimb Bio, Inc. Life Sciences 0.45 $627M Unlock rating and forecasts
184 DSGNDesign Therapeutics, Inc. Life Sciences 0.24 $609M Unlock rating and forecasts
185 WVEWave Life Sciences, Inc. Life Sciences 0.50 $609M Neutral +0.90% +1.97% ·
186 ZVRAZEVRA THERAPEUTICS, INC. Life Sciences 0.28 $608M Unlock rating and forecasts
187 PHATPhathom Pharmaceuticals, Inc. Life Sciences 0.17 $599M Unlock rating and forecasts
188 OLMAOlema Pharmaceuticals, Inc. Life Sciences 0.25 $595M Unlock rating and forecasts
189 IRWDIRONWOOD PHARMACEUTICALS INC Life Sciences 0.22 $595M Neutral +0.81% +2.80% ▼ 1
190 SLDBSolid Biosciences Inc. Life Sciences 0.13 $586M Unlock rating and forecasts
191 CRMDCorMedix Inc. Life Sciences 0.19 $581M Neutral +0.60% +2.15% ▲ 1
192 PRMEPrime Medicine, Inc. Life Sciences 0.20 $568M Unlock rating and forecasts
193 STTKShattuck Labs, Inc. Life Sciences 0.35 $535M Unlock rating and forecasts
194 CBIOGYRE THERAPEUTICS, INC. Life Sciences 0.10 $534M Unlock rating and forecasts
195 DBVTDBV Technologies S.A. Life Sciences 0.36 $525M Neutral +0.56% +2.02% ▲ 1
196 DRUGBRIGHT MINDS BIOSCIENCES INC. Life Sciences 0.22 $524M Unlock rating and forecasts
197 FTHFaeth Therapeutics, Inc. Life Sciences 0.06 $517M Unlock rating and forecasts
198 ACRSAclaris Therapeutics, Inc. Life Sciences 0.35 $514M Unlock rating and forecasts
199 CTMXCytomX Therapeutics, Inc. Life Sciences 0.07 $486M Unlock rating and forecasts
200 EOLSEvolus, Inc. Life Sciences 0.50 $477M Unlock rating and forecasts
151–200 of 304 Previous Next
Since the previous run

Rating changes

▲ 425▼ 593
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.